AM E3-SG3249 / IRBM - LARVOL DELTA

AM E3-SG3249, a first-in-class α-CRLF2 antibody-drug conjugate for the treatment of CRLF2-rearranged Ph-like B-ALL (AACR 2025) - "Moreover, AM E3-SG3249 treatment extended survival of hCRLF2-rearranged B-ALL orthotopic xenografts over standard induction therapy combining vincristine, dexamethasone, and L-asparaginase (VXL). AM E3 is a novel monoclonal antibody with ideal features for the development of a first-in-class α-CRLF2 ADC therapy. AM E3 conjugated with the cytotoxic agent tesirine (SG3249) demonstrated remarkable anti-tumor efficacy and a reasonable therapeutic window for the treatment of CRLF2-rearranged Ph-like B-ALL."

Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Leukemia • Oncology • CRLF2

IRBM to Disclose Strong Antitumor Efficacy of Novel Preclinical Agents Against Aggressive Brain Tumors and Acute Lymphoblastic Leukemia at AACR (PRNewswire) - "IRBM...announced today that it will be disclosing new data on two of its most promising internal assets at the upcoming American Association for Cancer Research (AACR) Annual Meeting....Potential first-in-class Antibody-Drug Conjugate (ADC) targeting CRLF2/TLSPR in 'Ph-like' B-ALL (AM E3-SG3249) demonstrated significant preclinical efficacy, representing a pioneering approach to treating hematologic cancer characterized by poor prognosis and high relapse rates, often affecting adolescents. Potential best-in-class brain permeable SHP2 allosteric inhibitor (I-1000233) exhibited promising results in preclinical studies, offering a new method of treating patients with RAS-driven malignancies, including challenging brain tumors and metastases."

Preclinical • B Acute Lymphoblastic Leukemia • Brain Cancer